https://www.biosciencedesk.com/news/abbvie-telisotuzumab-adizutecan-dual-fda-breakthrough-crc-nsclc-cmet-adc BioScienceDesk en 2026-10-07T17:20:12.008Z FDA Grants Two Breakthrough Therapy Designations to AbbVie's c-Met ADC Temab-A in Colorectal and Lung Cancer https://www.biosciencedesk.com/news/arrivent-firmonertinib-fails-phase-3-furvent-trial-egfr-exon-20-nsclc BioScienceDesk en 2026-10-06T00:00:00.000Z ArriVent's Firmonertinib Fails Pivotal Phase 3 FURVENT Trial in 1L EGFR Exon 20 NSCLC, Opening Multi-Billion Dollar Frontline Monopoly for Zipalertinib https://www.biosciencedesk.com/news/abbvie-genmab-epcoritamab-r-chop-phase-3-epcore-dlbcl-2 BioScienceDesk en 2026-10-05T00:00:00.000Z 24-Year Chemotherapy Hegemony Broken: Epcoritamab Slashes Frontline DLBCL Progression by 51% (HR 0.49) in Phase 3 EPCORE DLBCL-2 Trial https://www.biosciencedesk.com/news/astrazeneca-summit-dato-dxd-ivonescimab-phase-3-tnbc BioScienceDesk en 2026-10-05T00:00:00.000Z The $2 Billion Super-Alliance: AstraZeneca and Daiichi Sankyo Partner with Summit to Combine Dato-DXd (TROP2 ADC) and Ivonescimab in Frontline Phase 3 TNBC https://www.biosciencedesk.com/news/gotistobart-doubles-overall-survival-squamous-nsclc-preserve003-biontech-oncoc4 BioScienceDesk en 2026-10-04T00:00:00.000Z Docetaxel Shattered: Gotistobart Nearly Doubles Overall Survival (18.5 Months vs. 10.0 Months) in 2L Metastatic Squamous NSCLC, Resurrecting the Anti-CTLA-4 Class https://www.biosciencedesk.com/news/dethroning-tagrisso-fda-approves-rybrevant-lazcluze-1l-egfr-nsclc-mariposa BioScienceDesk en 2026-10-03T00:00:00.000Z Dethroning Tagrisso: FDA Approves Rybrevant Plus Lazcluze in 1L EGFR-Mutant NSCLC, Igniting a Fierce Efficacy vs. Toxicity Debate https://www.biosciencedesk.com/news/zipalertinib-files-fda-nda-frontline-egfr-exon20-nsclc-rezilient3 BioScienceDesk en 2026-10-02T00:00:00.000Z Zipalertinib Files for FDA Approval in Front-Line EGFR Exon 20 NSCLC: Phase 3 REZILIENT3 Trial Shatters Resistance Barrier https://www.biosciencedesk.com/news/ivonescimab-beats-keytruda-phase-3-harmoni-2-trial-nsclc BioScienceDesk en 2026-10-02T00:00:00.000Z Ivonescimab Beats Keytruda Head-to-Head: Phase 3 HARMONI-2 Trial Demonstrates 49% Reduction in Disease Progression https://www.biosciencedesk.com/news/illumina-launches-miseq-i100-series-room-temperature-sequencing BioScienceDesk en 2026-10-01T00:00:00.000Z Illumina Unveils MiSeq i100 Series with Room-Temperature Reagent Shipping and 4-Hour Run Times https://www.biosciencedesk.com/news/roche-receives-fda-clearance-elecsys-ptau217-alzheimers-blood-test BioScienceDesk en 2026-09-30T00:00:00.000Z Roche Receives FDA Clearance for Elecsys pTau217 Plasma Biomarker Assay in Alzheimer's Disease https://www.biosciencedesk.com/news/guardant-health-fda-approval-shield-blood-test-colorectal-cancer BioScienceDesk en 2026-09-29T00:00:00.000Z FDA Approves Guardant Health's Shield Blood Test as Primary Screening for Colorectal Cancer https://www.biosciencedesk.com/news/element-biosciences-closes-277m-series-d-for-aviti-global-expansion BioScienceDesk en 2026-09-28T00:00:00.000Z Element Biosciences Secures $277M Series D to Accelerate Global Commercial Scale-Up of AVITI System https://www.biosciencedesk.com/news/thermo-fisher-orbitrap-astral-mass-spectrometer-clinical-proteomics BioScienceDesk en 2026-09-27T00:00:00.000Z Thermo Fisher Scientific Showcases Orbitrap Astral Mass Spectrometer for High-Throughput Clinical Proteomics https://www.biosciencedesk.com/news/biorad-qx600-droplet-digital-pcr-6-color-multiplexing-validation BioScienceDesk en 2026-09-26T00:00:00.000Z Bio-Rad Demonstrates Advanced 6-Color Multiplexing on QX600 Droplet Digital PCR System https://www.biosciencedesk.com/news/vertex-crispr-casgevy-long-term-safety-durability-data-ash BioScienceDesk en 2026-09-25T00:00:00.000Z Vertex and CRISPR Therapeutics Present 3-Year Durability Data for Casgevy at Hematology Summit https://www.biosciencedesk.com/news/danaher-expands-life-sciences-bioprocessing-portfolio-with-abcam-integration BioScienceDesk en 2026-09-24T00:00:00.000Z Danaher Finalizes Global Integration of Abcam to Strengthen High-Affinity Reagents in Bioprocessing